HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37).

AbstractBACKGROUND:
Early clinical trials of HER2/neu-derived peptide vaccines indicate that they may be useful for preventing recurrence in breast cancer patients rendered disease-free after standard-of-care therapy. An effective vaccination strategy will probably require stimulation of T helper (Th) cells. AE37 is an HER2/neu-derived peptide that has been modified to enhance antigen-specific stimulation of Th cells by linkage of the Ii-Key moiety of the MHC class II-associated invariant chain (Ii protein).
OBJECTIVE:
To review the literature regarding the role of a Th response in immunotherapy with a focus on this novel HER2/neu-derived AE37 peptide.
RESULTS/CONCLUSION:
Improved immuno-genicity of the AE37 Ii-key hybrid peptide has been demonstrated in animal models, ex vivo patient cells, and, most recently, in a Phase I clinical trial in breast cancer patients. Future clinical trials incorporating AE37 into a peptide vaccine strategy are warranted.
AuthorsElizabeth A Mittendorf, Jarrod P Holmes, James L Murray, Eric von Hofe, George E Peoples
JournalExpert opinion on biological therapy (Expert Opin Biol Ther) Vol. 9 Issue 1 Pg. 71-8 (Jan 2009) ISSN: 1744-7682 [Electronic] England
PMID19063694 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • AE37 vaccine
  • Antigens, Differentiation, B-Lymphocyte
  • Cancer Vaccines
  • Histocompatibility Antigens Class II
  • invariant chain
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Receptor, ErbB-2
Topics
  • Animals
  • Antigens, Differentiation, B-Lymphocyte (immunology)
  • CD4-Positive T-Lymphocytes (immunology)
  • Cancer Vaccines (adverse effects, immunology)
  • Clinical Trials, Phase I as Topic
  • Granulocyte-Macrophage Colony-Stimulating Factor (pharmacology)
  • Histocompatibility Antigens Class II (immunology)
  • Humans
  • Neoplasms (immunology)
  • Receptor, ErbB-2 (immunology)
  • Vaccination

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: